

## IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1-27. (Cancelled)

28. (Currently Amended) A transdermal therapeutic system comprising a drug-containing adhesive matrix, in which the drug is rotigotine free-base ~~((-)-5,6,7,8-tetrahydro-6-(propyl-[2-(2-thienyl)ethyl]amino)-1-naphthol) in the form of a base or a prodrug of rotigotine~~, wherein the adhesive matrix contains **[[a]]** hot-melttable adhesive, the hot-melttable adhesive consisting of one adhesive or a mixture of different adhesives or of a mixture of an adhesive and a softener and exhibiting at 160°C a dynamic viscosity of not more than 100 Pa·s.

29. (Currently Amended) The transdermal therapeutic system of claim 28 wherein the ~~base form of~~ rotigotine free-base ~~or prodrug thereof~~ is dispersed or partly or completely dissolved in said hot-melttable adhesive.

30. (Currently Amended) The transdermal therapeutic system of claim 28 wherein the drug-containing adhesive matrix is produced by metering the ~~the base form of~~ rotigotine free-base ~~or prodrug thereof~~ into the solvent-free melt of the adhesive matrix at a temperature of between 120°C and 160°C.

31. (Previously Presented) The transdermal therapeutic system of claim 28 wherein the hot-melttable adhesive consists of a mixture of an amine-resistant silicone adhesive and at least one suitable softener.

32. (Previously Presented) The transdermal therapeutic system of claim 31 wherein the softener is an organic wax.

20 October 2009

33. (Previously Presented) The transdermal therapeutic system of claim 31 wherein the softener is ceresine or ozokerite.

34. (Currently Amended) The transdermal therapeutic system of claim 28 wherein the proportion of ~~the base form of~~ rotigotine free-base ~~or prodrug thereof~~ in the adhesive layer is 4 to 40 weight %.

35. (Currently Amended) The transdermal therapeutic system of claim 28 wherein the proportion of ~~the base form of~~ rotigotine free-base ~~or prodrug thereof~~ in the adhesive layer is 9 to 30 weight %.

36. (Currently Amended) The transdermal therapeutic system of claim 28 wherein the proportion of ~~the base form of~~ rotigotine free-base ~~or prodrug thereof~~ in the adhesive layer is 20 to 40 weight %.

37. (Cancelled)

38. (Withdrawn) The transdermal therapeutic system of claim 28 wherein the drug-containing adhesive matrix additionally contains an internal-phase component selected from the group consisting of

- (a) hydrophilic and amphiphilic polymers;
- (b) hydrophilic and amphiphilic copolymers;
- (c) mixtures of (a) and/or (b) with pharmaceutically acceptable softeners;
- (d) condensates from glycerin and fatty acids or polyols; and
- (e) suitable mixtures of the components (a)-(d).

39. (Withdrawn) The transdermal therapeutic system of claim 38 wherein the internal-phase component is selected from the group consisting of polysaccharides, substituted polysaccharides, polyethylene oxides, polyvinyl acetates, polyvinyl pyrrolidones, copolymers from polyvinyl pyrrolidone and (poly)vinyl acetate, polyethylene glycol, polypropylene

20 October 2009

glycol, copolymers from ethylene and vinyl acetate, glycerin-fatty acid esters and mixtures of polyvinyl alcohol with glycerin.

40. (Withdrawn) The transdermal therapeutic system of claim 28 wherein the adhesive matrix comprises:

- (a) 50-99 weight % of said hot-meltable adhesive;
- (b) 4-40 weight % rotigotine in the base form;
- (c) 0-40 weight % of an internal-phase component; and
- (d) 0-10 weight % of other adjuvants.

41. (Original) The transdermal therapeutic system of claim 28 wherein the hot-meltable adhesive is

- (a1) an EVA adhesive,
- (a2) an SxS adhesive, or
- (a3) a mixture of
  - (i) 70-99 weight % of an amine-resistant silicone adhesive and
  - (ii) 1-30 weight % of a suitable softener.

42-44. (Cancelled)

45. (Withdrawn and Currently Amended) A transdermal therapeutic system for administration of ~~Rotigotine~~ rotigotine, comprising: a layer that comprises ~~Rotigotine~~ rotigotine ~~or a prodrug of Rotigotine~~, wherein the layer

- (a) contains ~~Rotigotine~~ rotigotine ~~or prodrug thereof~~ in a percentile proportion of at least 20 weight %,
- (b) has a ~~Rotigotine~~ rotigotine ~~or prodrug thereof~~ content of at least 2.0 mg/cm<sup>2</sup>, and
- (c) optionally contains an organic wax and/or internal-phase component in an amount sufficient to retard the release of ~~the active substance~~ rotigotine.

20 October 2009

46. (Withdrawn and Currently Amended) The transdermal therapeutic system of claim 45 wherein ~~Rotigotine rotigotine or prodrug thereof~~ is transported through the skin at a steady-state flux rate of 100-500 µg per hour over a period of at least 5 days.

47. (Withdrawn and Currently Amended) The transdermal therapeutic system of claim 45 wherein ~~Rotigotine rotigotine or prodrug thereof~~ is transported through the human skin at a flux rate of 100-500 µg per hour over a period of at least 7 days.

48. (Withdrawn and Currently Amended) The transdermal therapeutic system of claim 45 wherein the system induces in the patient an average plasma concentration of 0.4 to 2 ng/ml ~~Rotigotine rotigotine~~ for a period of at least 5 days.

49-51. (Cancelled)

52. (Withdrawn and Currently Amended) A method for producing a transdermal therapeutic system that encompasses an adhesive matrix ~~comprises Rotigotine or a prodrug of Rotigotine as the drug~~ comprising rotigotine, the method comprising: prior to lamination, components of the adhesive matrix are melted and homogenized, solvent-free, at temperatures of between 70°C and 200°C.

53. (Withdrawn) The method of claim 52 wherein components of the adhesive matrix are melted and homogenized in an extruder.

54. (Withdrawn) The method of claim 52 wherein the hot-melting process takes place at temperatures between 120°C and 160°C.

55. (Withdrawn and Currently Amended) The method of claim 52 wherein ~~Rotigotine rotigotine or prodrug thereof~~ is introduced, in the adhesive matrix melt, in its solid state.

56. (Withdrawn and Currently Amended) The method of claim 52 wherein the adhesive

Serial No. 10/523,908

6102-000075/US/NP

RCE, Amendment C and Response to office action dated 21 July 2009, and Supp. IDS

20 October 2009

matrix, produced by the hot-melting process, contains ~~Rotigotine~~ rotigotine ~~or prodrug~~  
~~thereof~~ at a purity level of at least 98% as measured by HPLC at 220 nm and 272 nm.

57-59. (Cancelled)